Last 0.24 GBp
Change Today 0.00 / 0.00%
Volume 12.2M
VAL On Other Exchanges
Symbol
Exchange
London
As of 11:30 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

valirx plc (VAL) Snapshot

Open
0.24 GBp
Previous Close
0.24 GBp
Day High
0.24 GBp
Day Low
0.24 GBp
52 Week High
09/24/14 - 0.52 GBp
52 Week Low
12/18/14 - 0.20 GBp
Market Cap
7.9M
Average Volume 10 Days
18.5M
EPS TTM
-0.0011 GBp
Shares Outstanding
3.3B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALIRX PLC (VAL)

Related News

No related news articles were found.

valirx plc (VAL) Related Businessweek News

No Related Businessweek News Found

valirx plc (VAL) Details

ValiRx Plc, an investment holding company, engages in the research and development of technologies and products in oncology therapeutics and diagnostics in the United Kingdom. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of rebellious genes, which cause cancers, inflammatory conditions, and Alzheimer’s and autoimmune diseases. The company’s lead drug candidates in late stage pre-clinical development include VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that inhibits the process of apoptosis; and VAL201, a novel peptide for the treatment of hormone refractory prostate cancer, and other indications of hormone induced unregulated growth, including endometriosis. It is also developing ValiFinn BioMarkers that are diagnostic markers of inhibition of signaling pathways, which are target sites for novel drugs to treat cancer; and predictive markers of disease progression, as well as VAL401, a clinical drug to treat patients with lung cancer. The company was incorporated in 2000 and is based in London, the United Kingdom.

9 Employees
Last Reported Date: 03/28/14

valirx plc (VAL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 182.5K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 74.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 118.0K GBP
Compensation as of Fiscal Year 2013.

valirx plc (VAL) Key Developments

Valirx Plc Receives Patent Approval for Lead Therapeutic Compound VAL201

ValiRx Plc announced that it has received patent approval by the UK Patent Office regarding its lead therapeutic compound VAL201 for a further indication in endometriosis or hormone induced abnormal cell growth in women. Based on results in endometrial models, VAL201 has been shown to reduce abnormal endometrial growth, whilst leaving other hormone-induced activities working normally. Endometriosis is a gynaecological medical condition in which cells from the lining of the uterus (endometrium) appear and flourish outside the uterine cavity, most commonly on the ovaries. The uterine cavity is lined by endometrial cells, which are under the influence of female hormones.

ValiRx plc - Special Call

To discuss the successful first results from the VAL201 Clinical Trial

ValiRx plc Presents at 5th Annual Alembic Global Advisors Chemical Conference, Feb-25-2015

ValiRx plc Presents at 5th Annual Alembic Global Advisors Chemical Conference, Feb-25-2015 . Venue: Deer Valley, Utah, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 0.24 GBp 0.00

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies
 

Industry Analysis

VAL

Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 77.2x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 87.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.